the next mesoblast, page-13

yeah it's certainly no ordinary stock dolcevita, and it would appear there is much this equities analyst does not know about msb - their report should be amusing.

On another matter, I'll be interested to see if "they" can still keep the sp under $10 after November 14. As we know; 17,000 international cardiovascular specialists are expected to attend the American Heart Association annual conference in Orlando, Florida - where Dr Emerson C. Perin, Director of Research in Cardiovascular Medicine and Medical Director, Stem Cell Center, Texas Heart Institute, Houston will present Revascor trial results.

To quote Professor Itescu: "This forum provides an excellent opportunity for a wide audience of cardiovascular experts to be exposed to Mesoblast's proprietary cutting-edge technology and our robust clinical results."

Go The Blast! :)